St. Jude Children’s Research Hospital scientists have identified the primary target of the experimental cancer drug CX-5164, revealing a possible risk for late effects of treatment. (IMAGE)

St. Jude Children's Research Hospital

St. Jude Children’s Research Hospital scientists have identified the primary target of the experimental cancer drug CX-5164, revealing a possible risk for late effects of treatment.

Caption

“These new details of CX-5461’s mechanism of action in cancer treatment have potentially important safety implications for patients,” said Paul Geeleher, Ph.D., St. Jude Department of Computational Biology. The first author is Min Pan, Ph.D., a scientist in the Geeleher lab.

Credit

St. Jude Children's Research Hospital

Usage Restrictions

N/A

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.